Q-omics provides the consensus-scored MTND4P20 profile across patient tissues and cancer cell-line models. MTND4P20 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MTND4P20 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, MTND4P20 RNA expression shows 10,938 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KICH, LIHC, and ESCA as cancer lineages where MTND4P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND4P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND4P20 survival associations across molecular data types. MTND4P20 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND4P20 RNA expression–survival associations across cancer types. High MTND4P20 expression shows unfavorable associations in KICH, KIRC, ACC, LUAD and UCEC, but favorable associations in LIHC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MTND4P20 RNA expression.
This table summarizes MTND4P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MTND4P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND4P20 shows lower tumor expression in LIHC, KICH, BRCA and CHOL and higher tumor expression in KIRP and KIRC. The LIHC box plot shows higher MTND4P20 RNA expression in normal versus tumor tissue (log2 FC = −1.750, t-test p < 0.001).
This table shows molecular features associated with MTND4P20 in patient tissues and cancer cell lines. In patient samples, MTND4P20 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
